Biophytis (Euronext Paris: ALBPS.PA) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for age-related diseases. The Company has two clinical-stage product candidates in development: Sarcob (BIO101) and Maculia (BIO201). Sarcob is a small molecule for the treatment of sarcopenic obesity designed to slow muscle atrophy. Initial signs of clinical activity were demonstrated in a Phase I/II study in healthy, obese volunteers. The Company is preparing to initiate a randomized Phase IIb trial for Sarcob in the second half of 2016. The Company’s second product candidate is Maculia, a PPAR agonist for the treatment of dry age-related macular degeneration (AMD). Preclinical data indicate that Maculia may reduce oxidative stress in cells of the retina. Biophytis is preparing to initiate a Phase IIb study for Maculia in the second half of 2016.